Spectra-Scope – World Leading Laser & AI-based Skin Cancer Diagnostic Technology
Detect the Invisible in an Instant
Most skin cancers—especially melanoma and squamous cell carcinoma—present higher risks when left untreated for an extended period. However, skin cancer diagnosis is a time-consuming process that almost always takes over a week to confirm. Thanks to the development of Speclipse Spectra-Scope®, a nearly instantaneous skin cancer diagnosis is now workable for physicians.
Spectra-Scope® is quick, safe and easy to use. To evaluate the degree of atypia in a lesion, measurements are performed on a reference area close to the lesion, as well as on the lesion itself. The procedure takes only a second, and the LIPS score and the corresponding clinical predictive value of the lesion are displayed within a few seconds.
Spectra-Scope® is quick, safe and easy to use. To evaluate the degree of atypia in a lesion, measurements are performed on a reference area close to the lesion, as well as on the lesion itself. The procedure takes only a second, and the LIPS score and the corresponding clinical predictive value of the lesion are displayed within a few seconds.
Unprecedented accuracy in sensitivity (97%) and
specificity (86%) proven in worldwide clinical studies
Spectra-Scope’s® diagnostic accuracy has been proven by worldwide clinical studies
in the United States and Australia.
A series of clinical studies were used to evaluate the effectiveness and safety of Spectra-Scope®.
A deep learning-based algorithm was used to create a robust database of information, leading to ground-breaking accuracy in both sensitivity and specificity.
The identification of skin cancers (BCC, SCC and malignant melanoma) vs. benign lesions were accurately diagnosed with 97.6% sensitivity and 86.2% specificity.
1 Increase Early Diagnosis Accuracy
Lesions that are secondarily verified by Spectra-Scope® have a higher chance of being correctly diagnosed as positive through biopsy.
2 Improve Efficiency
The detailed visual examination of challenging lesions to determine diagnosis and treatment is time consuming. Spectra-Scope® can scan these lesions and provide verification in a matter of seconds without compromising clinical accuracy.
3 Reduced the Number of Unnecessary Biopsy
Challenging lesions can be verified by Spectra-Scope® before being sent for biopsy, avoiding unnecessary biopsies of benign lesions.
